Phenmetrazine Hydrochloride in Treatment of Obesity

Abstract

Phenmetrazine hydrochloride is the approved name of the compound 2-phenyl-3-methyl-tetrahydroxazine hydrochloride, marketed under the trade name of " preludin." It is related to ephedrine and has chemical and pharmacological similarities to amphetamine. In

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

“…Preludin has sympathomimetic properties similar to that of ephedrine and amphetamine and thus inhibits food intake by stimulating the release of norepinephrine and dopamine from CNS nerve terminals (Ressler, 1957;Szenas and Pattee, 1957;Leith and Beck, 1958;Rothman and Baumann, 2006). Preludin was commonly administered thrice daily in an amount of 25 mg, and, when given in adjunct to a calorierestricted diet, placebo-subtracted weight loss induced by preludin is typically about ;0.5 kg/wk with significant improvement of blood glucose after 4-6 weeks of treatment (Robillard, 1957;Leith and Beck, 1958;Briggs et al, 1960;Baggio et al, 2004). Adverse effects associated with phenmetrazine include tachycardia, heart arrhythmias, hypertension, convulsions, restlessness, agitation, vomiting, and diarrhea (Clarke, 2007).…”